Discount Code (0% Off) has been applied.
 
Enter a search term.

If you can't find what you were looking for, please contact us using one of the methods below so we can better serve you.

1 (800) 854-7220
answers@mcguff.com Suggest an Item
Ondansetron Injection 2 mg/mL, Single Dose Vial 2 mL, Each
Manufacturer: Apotex

Ondansetron Injection 2 mg/mL, Single Dose Vial 2 mL, Each

$4.99
Item Code: 009205
Mfg Part #: 60505-6130-05
This product is only available to licensed healthcare professionals.
Select your shipping method. This is helpful to expedite a portion of your order.
To reduce overall packaging and shipping costs, our shipping department will pack your orders in as few boxes as possible. Compounded drugs must ship separately from our other products. When choosing Next Day or 2nd Day Air shipping methods, final shipping totals will be calculated when your order is packed and invoiced. Box size and package destination does not affect shipping fee calculations. The number of boxes is determined by size, weight and quantity of products ordered. For additional information or questions, please contact us.
  Usually ships within 24 hours.

Ondansetron Injection, USP is a sterile, nonpyrogenic solution for intravenous (IV) or intramuscular (IM) use, designed to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea and vomiting. Ondansetron is a selective 5-HT3 receptor antagonist, providing effective antiemetic relief.

 

Key Benefits:

  • Prevention of Nausea and Vomiting: Effective against chemotherapy-induced nausea and postoperative nausea and vomiting, making it essential in oncology and surgical care.
  • Multiple Administration Routes: Administered via IV or IM, providing flexibility based on patient needs and clinical setting.
  • Clinically Tested: Approved since 1991, widely trusted in oncology and post-surgical care.

 

Dosage and Administration:

For Intravenous or Intramuscular Use with dilution recommended in specific cases:

  • Chemotherapy-Induced Nausea and Vomiting (Adults and Pediatric Patients 6 Months+): 0.15 mg/kg per dose, administered as three doses over 15 minutes, beginning 30 minutes prior to chemotherapy and continuing 4 and 8 hours after the first dose.
  • Postoperative Nausea and Vomiting (Adults and Pediatric Patients 1 Month+): Recommended single dose is 4 mg IV or IM, with administration prior to anesthesia or postoperatively if symptoms occur.

 

Why Choose Ondansetron Injection?

  • Proven Antiemetic Effectiveness: Effective in managing nausea and vomiting linked to chemotherapy and surgeries.
  • Flexible Dosing and Compatibility: Available in 4 mg/2 mL single-dose vials, designed to accommodate diverse patient needs.
  • Safe and Sterile: Supplied as a clear, colorless solution, manufactured under stringent conditions to meet safety standards.

 

Warnings:

  • QT Prolongation and Torsade de Pointes: Can prolong QT interval; monitor patients with risk factors for arrhythmias.
  • Serotonin Syndrome Risk: Increased risk when used with other serotonergic drugs.
  • Hypersensitivity Reactions: Anaphylactic reactions may occur in patients with previous 5-HT3 antagonist sensitivity.

 

Disclaimer:

This product description was generated by AI and is intended for informational purposes only. Please consult the latest package insert.

Products specifications
Medical License Required Yes
Class Rx
Product Name Injection
Generic Name Ondansetron
Route of Administration Intravenous (IV), Intramuscular (IM)
Strength 2 mg/mL
Volume 30 mL
Container Single Dose Vial
Storage Requirements Protect from Light
Storage Temperature 2º to 30ºC (36º to 86ºF)
Therapeutic Class Antiemetics
Unit of Measure Each

Ondansetron Injection, USP is a sterile, nonpyrogenic solution for intravenous (IV) or intramuscular (IM) use, designed to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea and vomiting. Ondansetron is a selective 5-HT3 receptor antagonist, providing effective antiemetic relief.

 

Key Benefits:

  • Prevention of Nausea and Vomiting: Effective against chemotherapy-induced nausea and postoperative nausea and vomiting, making it essential in oncology and surgical care.
  • Multiple Administration Routes: Administered via IV or IM, providing flexibility based on patient needs and clinical setting.
  • Clinically Tested: Approved since 1991, widely trusted in oncology and post-surgical care.

 

Dosage and Administration:

For Intravenous or Intramuscular Use with dilution recommended in specific cases:

  • Chemotherapy-Induced Nausea and Vomiting (Adults and Pediatric Patients 6 Months+): 0.15 mg/kg per dose, administered as three doses over 15 minutes, beginning 30 minutes prior to chemotherapy and continuing 4 and 8 hours after the first dose.
  • Postoperative Nausea and Vomiting (Adults and Pediatric Patients 1 Month+): Recommended single dose is 4 mg IV or IM, with administration prior to anesthesia or postoperatively if symptoms occur.

 

Why Choose Ondansetron Injection?

  • Proven Antiemetic Effectiveness: Effective in managing nausea and vomiting linked to chemotherapy and surgeries.
  • Flexible Dosing and Compatibility: Available in 4 mg/2 mL single-dose vials, designed to accommodate diverse patient needs.
  • Safe and Sterile: Supplied as a clear, colorless solution, manufactured under stringent conditions to meet safety standards.

 

Warnings:

  • QT Prolongation and Torsade de Pointes: Can prolong QT interval; monitor patients with risk factors for arrhythmias.
  • Serotonin Syndrome Risk: Increased risk when used with other serotonergic drugs.
  • Hypersensitivity Reactions: Anaphylactic reactions may occur in patients with previous 5-HT3 antagonist sensitivity.

 

Disclaimer:

This product description was generated by AI and is intended for informational purposes only. Please consult the latest package insert.

Products specifications
Medical License Required Yes
Class Rx
Product Name Injection
Generic Name Ondansetron
Route of Administration Intravenous (IV), Intramuscular (IM)
Strength 2 mg/mL
Volume 30 mL
Container Single Dose Vial
Storage Requirements Protect from Light
Storage Temperature 2º to 30ºC (36º to 86ºF)
Therapeutic Class Antiemetics
Unit of Measure Each

Coronavirus (COVID-19)

Due to the Coronavirus (COVID-19) outbreak worldwide, the global demand for some Personal Protective Equipment (PPE) is exceeding current supply availability.

In addition, the manufacturing of the PPE and many other wound care/infection prevention products have been impacted by the global response to the Coronavirus. While you may see product availability reduction in the near-term, please be assured that we at McGuff Medical are continuing to work diligently to ensure an uninterrupted supply of products and alternative products to you.

Additionally, in order to ensure healthcare providers have access to the PPEs they need, the McGuff Company is temporarily limiting PPEs to healthcare providers.

As always, please feel free to reach out to our McGuff Customer Service team with any questions that you may have.

Click here for updates regarding Coronavirus Pandemic and Your Supplies and a message from our President